Given the important role of LIMK1 and CDK5 in tumor metastasis, the LIMK1 inhibitor BMS‐5 and CDK5 inhibitor Dinaciclib were employed to evaluate the potential of targeted therapy. This evidence concerns the gene CDK5 and neoplasm.